Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism
Stavros V. Konstantinides, Eric Vicaut, Thierry Danays, Cecilia Becattini, Laurent Bertoletti, Jan Beyer-Westendorf, Helene Bouvaist, Francis Couturaud, Claudia Dellas, Daniel Duerschmied, Klaus Empen, Emile Ferrari, Nazzareno Galiè, David Jiménez, Maciej Kostrubiec, Matija Kozak, Christian Kupatt, Irene M. Lang, Mareike Lankeit, Nicolas Meneveau, Massimiliano Palazzini, Piotr Pruszczyk, Matteo Rugolotto, Aldo Salvi, Olivier Sanchez, Sebastian Schellong, Bozena Sobkowicz and Guy Meyer
Thrombolysis for Pulmonary Embolism: Kaplan-Meier Survival Curves of Patients Randomized to Tenecteplase Compared With Placebo
Kaplan-Meier curves showing the cumulative risk of death in patients with intermediate-risk pulmonary embolism who were randomized to tenecteplase versus placebo in the PEITHO (Pulmonary Embolism Thrombolysis) trial. A total of 709 patients, corresponding to 71% of the overall intention-to-treat population, were randomized by 28 study sites that signed the third protocol amendment extending the follow-up period to at least 24 months. Long-term follow-up extended over a median period of 37.8 months, with an interquartile range of 24.6 to 54.8 months. Survival status was assessed in 353 of 359 (98.3%) patients in the thrombolysis arm and in 343 of 350 (98.0%) patients in the placebo arm. Overall long-term mortality rates did not differ significantly between the 2 treatment arms: 20.3% and 18.0%, respectively (log-rank; p = 0.43).